AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 277 filers reported holding AMICUS THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.99 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $1,220,000 | +87.4% | 127,800 | +89.3% | 0.00% | 0.0% |
| Q2 2021 | $651,000 | +22.6% | 67,500 | +193.7% | 0.00% | – |
| Q4 2020 | $531,000 | +101.1% | 22,980 | +22.9% | 0.00% | – |
| Q3 2020 | $264,000 | -87.6% | 18,704 | -89.0% | 0.00% | -100.0% |
| Q2 2019 | $2,122,000 | +212100.0% | 170,052 | +197634.9% | 0.00% | – |
| Q4 2018 | $1,000 | -99.9% | 86 | -99.9% | 0.00% | -100.0% |
| Q3 2018 | $852,000 | -51.4% | 70,514 | -37.2% | 0.00% | -66.7% |
| Q2 2018 | $1,753,000 | -75.5% | 112,225 | -76.4% | 0.00% | -66.7% |
| Q1 2018 | $7,142,000 | -16.0% | 474,825 | -19.6% | 0.01% | -18.2% |
| Q4 2017 | $8,499,000 | -0.8% | 590,573 | +3.9% | 0.01% | -21.4% |
| Q3 2017 | $8,569,000 | +2026.3% | 568,323 | +1320.8% | 0.01% | +1300.0% |
| Q2 2017 | $403,000 | +41.4% | 40,000 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $285,000 | -83.2% | 40,000 | -67.0% | 0.00% | -75.0% |
| Q3 2015 | $1,694,000 | – | 121,089 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |